Logo American Journal of Case Reports

Call: 1.631.629.4328
Mon-Fri 10 am - 2 pm EST

Contact Us

Logo American Journal of Case Reports Logo American Journal of Case Reports Logo American Journal of Case Reports

29 September 2020: Articles  Poland

A 63-Year-Old Woman with SARS-CoV-2 Infection, Who Developed Severe COVID-19 Pneumonia and Was Supported with Convalescent Plasma Therapy

Unusual clinical course, Diagnostic / therapeutic accidents, Unusual setting of medical care, Unexpected drug reaction , Educational Purpose (only if useful for a systematic review or synthesis)

Anna Moniuszko-Malinowska ** , Piotr Czupryna * , Barbara Boczkowska-Radziwon B , Tomasz Wasiluk B , Karol Borawski B , Justyna Dunaj B , Magdalena Bujno B , Piotr Radziwon B , Krzysztof Rutkowski D , Sławomir Pancewicz A

DOI: 10.12659/AJCR.927662

Am J Case Rep 2020; 21:e927662

0 Comments

Abstract

BACKGROUND: There is no evidence-based treatment for coronavirus disease 2019 (COVID-19). We report the case of a 63-year-old woman with SARS-CoV-2 infection who developed severe COVID-19 pneumonia and was treated with convalescent plasma.

CASE REPORT: A 63-year-old woman who presented with severe and prolonged course of COVID-19 disease (fever up to 39.4°C, persistent cough, and dyspnea) received a convalescent plasma transfusion, which led to complete recovery. The diagnosis was confirmed by RT-PCR testing using the CFX96 Real-Time System (Bio-Rad, USA) from nasopharyngeal swabs. In laboratory tests, an increase in acute-phase parameters was observed. Chest computed tomography (CT) showed abnormalities typical for COVID-19. On days 9 and 11 of the disease, she received the convalescent plasma prepared from a single plasmapheresis donation from a male donor. This male donor was qualified as a convalescent plasma donor according to Polish guidelines, which are compliant with European guidelines. He donated plasma at the Regional Centre for Transfusion Medicine in Białystok, Poland. The therapy with convalescent plasma led to clinical improvement and normalization of inflammatory parameters.

CONCLUSIONS: This report presents a case of severe COVID-19 pneumonia in a 63-year-old woman who was given supportive treatment with convalescent plasma. Ongoing clinical trials will determine whether convalescent plasma therapy is an effective treatment for SARS-CoV-2 infection.

Keywords: Antibodies, Complementary Therapies, COVID-19, Blood Component Transfusion, COVID-19, Coronavirus Infections, Follow-Up Studies, Middle Aged, Pandemics, Pneumonia, Viral, RNA, Viral, Real-Time Polymerase Chain Reaction, Risk Assessment, severe acute respiratory syndrome, Treatment Outcome

Background

The virus that causes coronavirus disease 2019 (COVID-19) is a beta coronavirus related to Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2). The new virus originated in China and since December 2019 it has spread throughout the world, causing over 21.8 million cases and 773 000 deaths, and the pandemic is still ongoing [1].

SARS-CoV-2 is transmitted by airborne droplets during coughing or sneezing and by close contact with infected individuals. The expression of angiotensin-converting enzyme-2 (ACE-2) receptor in the upper-respiratory tract correlates with the course of virus infection. SARS-CoV-2 utilizes ACE-2 as a receptor to enter host pneumocytes, which may explain its high infectivity. Moreover, comorbidities, such as diabetes, hypertension, heart diseases, and obesity, influence the course of COVID-19 [2].

The diagnosis of SARS-CoV-2 infections relies on PCR in samples taken from the upper- or lower-respiratory tract. The detection of antibodies against SARS-CoV-2 in blood may be useful. In symptomatic cases, chest CT plays a crucial role, as it reveals abnormalities, such as ground-glass lesions, patchy consolidations, alveolar exudates, and interlobular involvement, eventually indicating deterioration.

To date, no curative treatment has been found. There are no specific antiviral agents that target the novel virus, but other treatment methods, including plasma obtained from COVID-19 convalescents, are under investigation [3]. We report the case of a patient treated with plasma obtained from a convalescent patient, which led to a complete recovery.

Case Report

A 63-year-old woman with type 2 diabetes and hypertension, without any other risk factors, was referred to the Department of Infectious Diseases and Neuroinfections, Medical University of Białystok, Poland due to fever and cough. Her husband and daughter had been diagnosed with COVID-19. The sample taken from the patient in the Outpatient Department was positive for SARS-CoV-2. The diagnosis was made by reverse transcription-polymerase chain reaction (RT-PCR) testing using the CFX96 Real-Time System (Bio-Rad, USA) from nasopharyngeal swabs. Detection was made with the Seegene (CE-IVD) diagnostic kit. Three regions were detected: RdRP, N, and E.

There were no significant abnormalities on physical examination. Chest computed tomography (CT) on day 2 of admission revealed lesions suggestive of COVID-19 pneumonia (Figure 1A, 1B).

Despite 9 days of treatment with oral chloroquine (2×250 mg), the patient remained pyrexial up to 39.4°C and had persistent cough and dyspnea. There was an increase in acute-phase parameters (Table 1). A chest CT scan performed on day 8 showed progression of inflammatory changes (Figure 1C, 1D).

On days 9 and 11, she was given 250 mL of convalescent plasma intravenously, both prepared from a single plasmapheresis donation from a male donor. The donor had mild COVID-19 symptoms (1-day fever and loss of taste and smell). He was presumed healthy after 2 negative PCR test results. He was a suitable convalescent plasma donor according to Polish and European guidelines [4] and donated plasma at the Regional Centre for Transfusion Medicine in Białystok, Poland on 19.05.2020. After donation, the plasma was split into 3 equal portions. A pathogen reduction process involving the use of methylene blue (Macotronic, Macopharma, France) was applied to 2 portions, and the third was pathogen-reduced with amotosalen hydrochloride (Intercept, Cerus, USA). The plasma was frozen and kept at below −25°C until release. The plasma contained anti-SARS-CoV-2 antibodies: IgA >7 (positive >1.1), IgG – 8.37 (positive >1.1), IgG titer 1: 1500 (Euroimmun, USA) and IgG 57.60 AU/ml (positive >15 AU/ml) (DiaSorin, Italy).

The patient responded well to plasma therapy, with fever resolution, clinical improvement, and normalization of inflammatory parameters (Table 1). Subsequent PCR tests were negative 3 times. A change in anti-SARS-CoV-2 IgG antibodies titer was observed. Before infusion, the titer was 81.4 AU/ml (28.05). After the first infusion, the titer was 172 AU/ml (31.05). After the second infusion, the titer was 247 AU/ml (01.06) (DiaSorin, Italy). A repeat CT chest (day 20) showed regression of inflammatory changes (Figure 1E, 1F).

The patient was discharged on day 23 in good general condition. There were no treatment complications. At follow-up 6 weeks after discharge, she reported no symptoms, and all laboratory parameters were within normal ranges (Table 1).

Discussion

The quest for COVID-19 treatment continues. Thus far, there is not enough data to support the effectiveness of any particular treatment. Therefore, all data on various COVID-19 treatments are valuable.

There have been very few reports on the usefulness of convalescent plasma transfusions to treat COVID-19. They included a few case series, but no clinical trials. Their outcomes were encouraging, as improvement was observed in all patients treated with convalescent plasma, despite a severe course of the disease [5,6]. Convalescent plasma can lead to direct neutralization of the virus, modification of an overactive immune system (cytokine storm, Th1/Th17 ratio, complement activation), and a hypercoagulable state [7].

In 2015 Mair-Jenkins et al. reported that convalescent plasma transfusion may be beneficial for patients with viral severe acute respiratory infections. A meta-analysis of 32 studies on SARS coronavirus infections and severe influenza proved that transfusion of convalescent plasma had a clinically relevant impact in reducing the rate of mortality and viral load in these patients [8].

Studies performed during ongoing coronavirus pandemics confirm that patients with a severe infection can benefit from convalescent plasma transfusion and that the risk of adverse effects of such therapy is rather low [4,6,9–11]. The most common adverse reactions are transfusion-related events, involving rigors, fever, anaphylaxis, transfusion-related acute lung injury, circulatory overload, and hemolysis.

Therapy seems to be more effective if implemented during first 2 weeks after the onset of symptoms. Therefore, the optimal timing of administering convalescent plasma on COVID-19 needs to be carefully considered [12].

Our report confirms the beneficial effects of convalescent plasma in a patient with severe COVID-19 disease with complete resolution of symptoms and an increase in serum antibody titers after each transfusion and no adverse effects.

Convalescent plasma transfusion is one of the supportive treatment options for COVID-19. Ongoing clinical trials [13] may generate robust data on this promising treatment modality.

Conclusions

This report presents a case of severe COVID-19 pneumonia in a 63-year-old woman who was given supportive treatment with convalescent plasma. The results of ongoing controlled clinical trials are awaited to determine whether convalescent plasma therapy is an effective treatment for SARS-CoV-2 infection.

References:

1.. https//covid19.who.int/

2.. Zhou P, Yang YL, Wang XG: Nature, 2020; 579; 270-73

3.. Lu H: Biosci Trends, 2020; 14; 69-71

4.. : Ref. Ares, 2020 3256185–23/06/2020, https://ec.europa.eu/health/sites/health/files/blood_tissues_organs/docs/guidance_plasma_covid19_en.pdf

5.. Shen Ch, Wang Z, Zhao F: JAMA, 2020; 323(16); 1582-89

6.. Duan K, Liu B, Li C: PNAS, 2020; 117(17); 9490-96

7.. Rojas M, Rodríguez Y, Monsalve DM: Autoimmun Rev, 2020; 19(7); 102554

8.. Mair-Jenkins J, Saavedra-Campos M, Baillie JK: J Infect Dis, 2015; 211(1); 80-90

9.. Chen L, Xiong J, Bao L, Shi Y: Lancet Infect Dis, 2020; 20(4); 398-400

10.. Valk SJ, Piechotta V, Chai KL: Cochrane Database Syst Rev, 2020; 5(5); CD013600

11.. Harvala H, Mehew J, Robb ML: Euro Surveill, 2020; 25(28); 2001260

12.. Zhao Q, He Y: J Clin Virol, 2020; 127; 104358

13.. Casadevall A, Joyner MJ, Pirofski LA: JAMA, 2020; 324(5); 455-57

SARS-CoV-2/COVID-19

19 May 2022 : Case report  Serbia

Bilateral Emphysematous Pyelonephritis Associated with COVID Pneumonia: A Case Report

Am J Case Rep In Press; DOI: 10.12659/AJCR.936370  

17 May 2022 : Case report  USA

High-Frequency Oscillatory Ventilation for Refractory Hypoxemia in Severe COVID-19 Pneumonia: A Small Case ...

Am J Case Rep In Press; DOI: 10.12659/AJCR.936651  

13 May 2022 : Case report  Japan

A case of exacerbation of haloperidol-induced rhabdomyolysis following the onset of COVID-19

Am J Case Rep In Press; DOI: 10.12659/AJCR.936589  

13 May 2022 : Case report  USA

Acute Disseminated Encephalomyelitis After SARS-CoV-2 Vaccination

Am J Case Rep In Press; DOI: 10.12659/AJCR.936574  

In Press

23 May 2022 : Case report  Switzerland

Pharmacological and Behavioral Strategies to Improve Vision in Acquired Pendular Nystagmus

Am J Case Rep In Press; DOI: 10.12659/AJCR.935148  

23 May 2022 : Case report  USA

A Case of Methicillin-Sensitive Staphylococcus aureus (MSSA) Prostate Abscess, Osteomyelitis, and Myositis ...

Am J Case Rep In Press; DOI: 10.12659/AJCR.936704  

23 May 2022 : Case report  USA

Adalimumab Mitigates Lumbar Radiculopathy in a Case of Ankylosing Spondylitis

Am J Case Rep In Press; DOI: 10.12659/AJCR.936600  

20 May 2022 : Case report  Canada

Diagnostic Puzzle of Acute Ischemic Stroke Mimics – Seizure Versus Post-Stroke Recrudescence: A Case Report

Am J Case Rep In Press; DOI: 10.12659/AJCR.936826  

Most Viewed Current Articles

23 Feb 2022 : Case report  USA

Penile Necrosis Associated with Local Intravenous Injection of Cocaine

DOI :10.12659/AJCR.935250

Am J Case Rep 2022; 23:e935250

17 Feb 2022 : Case report  Oman

Myocarditis, Pulmonary Hemorrhage, and Extensive Myositis with Rhabdomyolysis 12 Days After First Dose of P...

DOI :10.12659/AJCR.934399

Am J Case Rep 2022; 23:e934399

06 Dec 2021 : Case report  Brazil

Lipedema Can Be Treated Non-Surgically: A Report of 5 Cases

DOI :10.12659/AJCR.934406

Am J Case Rep 2021; 22:e934406

19 Feb 2022 : Case report  USA

A Rare Case of Coronavirus Disease 2019 Vaccine-Associated Cerebral Venous Sinus Thrombosis Treated with Me...

DOI :10.12659/AJCR.935355

Am J Case Rep 2022; 23:e935355

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

American Journal of Case Reports eISSN: 1941-5923
American Journal of Case Reports eISSN: 1941-5923